- cafead   May 13, 2022 at 11:02: AM
via Despite an ongoing strategic review that might alter Sandoz’s future, the Novartis generics engine keeps churning out new products.
Sandoz has launched the first fully substitutable U.S. generic of Roche’s blockbuster idiopathic pulmonary fibrosis (IPF) therapy Esbriet, the Novartis unit said Thursday.
article source
Sandoz has launched the first fully substitutable U.S. generic of Roche’s blockbuster idiopathic pulmonary fibrosis (IPF) therapy Esbriet, the Novartis unit said Thursday.
article source